Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123017 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02123017 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT02123017, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with escalating doses of lactulose to be used as a preparation for colonoscopy.
Interventions
- DRUG 90 grams of Crystalline Lactulose
- DRUG 135 grams of Crystalline Lactulose
- DRUG 180 grams of Crystalline Lactulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02123017
The ClinicalTrials.gov registry entry for NCT02123017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 90 grams of Crystalline Lactulose is the first listed.
NCT02123017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02123017 about?
NCT02123017 is a clinical study titled "Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy". The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with escalating doses of lactulose to be used as a preparation for colonoscopy.
What is the current status of trial NCT02123017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-04. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02123017?
The interventions under investigation include: 90 grams of Crystalline Lactulose (DRUG), 135 grams of Crystalline Lactulose (DRUG), 180 grams of Crystalline Lactulose (DRUG).
Who is sponsoring clinical trial NCT02123017?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.